-
-
-
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
The authors performed a descriptive analysis of all cases of desquamative inflammatory vaginitis (DIV), defined as symptomatic vaginitis (discharge, dyspareunia, pruritus, burning, or irritation) associated with vaginal inflammation (such as focal or linear erosions), a vaginal pH higher than 4.5, and saline microscopy showing an increase in parabasal and inflammatory cells in the absence of an infectious etiology (such as trichomonas, candida, or bacterial vaginosis).
-
Understanding sexual pain remains limited. With multiple etiologies and lack of evidence-based outcomes research, future investigations should focus on evaluating the intimacy of the couple, the partner relationship, and biomedical sources of pain such as the pelvic floor muscles.
-
While adolescents are at risk for HIV, many forego testing. This lack of testing is a major public health concern, as more than 50% of HIV-infected adolescents do not know their infection status.
-
Thumbing through your inbox charts, you see your next patient is a 19-year-old who began use of oral contraceptives (OCs) about six months ago. When you talk with her in the examination room, however, you find that she has discontinued use of the Pill after she began to gain weight.
-
-
The U.S. Occupational Safety and Health Administration (OSHA) briefly reopened the comment period on the proposed rule to record work-related musculoskeletal disorders (MSDs). The comments came from May 17 to June 16, about a month after two teleconferences focused on concerns of small businesses.
-
Occupational health nurses noticed that employees were reporting skin irritation from wearing safety goggles, and reported this to safety. After safety reviewed the situation, a new process was implemented for cleaning the goggles.